

Stock Sentiment Analysis Report

Illumina (ILMN)

Analysis Period: 2026-02-26 to 2026-03-28 (30 days)

Generated: 2026-03-28 08:59:43

Executive Summary

Executive Summary: Illumina (ILMN) Sentiment Analysis (2026-02-26 to 2026-03-28)

Sentiment analysis for Illumina (ILMN) during the period of February 26 to March 28, 2026, indicates a predominantly neutral to slightly negative market perception. Out of 92 tracked items, 43 (46.7%) were classified as neutral, 28 (30.4%) as negative, and 21 (22.8%) as positive. Key drivers for positive sentiment included instances of ILMN stock outperforming competitors and reports of stronger-than-expected Q3 earnings and FY2026 guidance. Conversely, negative sentiment was primarily driven by bearish stock price forecasts and observed declines in share value. The prevalence of neutral commentary suggests a cautious or wait-and-see approach from a significant portion of market observers.

Significant positive events included Illumina's stock rising by 2.96% on a strong trading day, outperforming broader market indices, and the expansion of its precision oncology testing partnership with Labcorp to advance next-generation sequencing (NGS). On the negative side, a notable event was the forecast of Illumina's price giving in to negative pressure, with analysts predicting further decline and targeting a key support level. While several highly negative sentiment items were identified, many originated from scientific research publications, which may not directly reflect the company's immediate financial performance or market sentiment.


Sentiment Breakdown

Category	Count	Percentage
Positive	21	22.8%
Negative	28	30.4%
Neutral	43	46.7%
Total	92	100.0%

Overall Sentiment: MIXED

Sentiment Trend Over Time

illumina (ILMN) - Sentiment Trend (30 Days)



Key Findings

Finding
✓ Illumina Inc. stock outperforms competitors on strong trading day
✓ Is Illumina (ILMN) a Great Long-Term Investment?
✓ Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. \$ILMN
✗ Recalibrating the epigenetic clock reveals divergent DNA methylation age signatures across schizophrenia, bipolar disorder and major depressive disorder.
✗ hsa-miR-1246 is Consistently Overexpressed in Spheroid-Derived Cancer Stem Cells From Multiple Tumor Types.
✗ Illumina price gives in to negative pressure - Forecast today - 24-03-2026

Top Positive Events

Title	Source	Date	Score
Illumina Inc. stock outperforms competitors on str...	alpha_vantage	2026-03-19	0.711
Is Illumina (ILMN) a Great Long-Term Investment?	reddit	2026-03-22	0.625

Quinn Opportunity Partners LLC Sells 62,423 Shares...	alpha_vantage	2026-03-15	0.612
What are you doing? You really think I'm going to ...	reddit	2026-02-26	0.603
Illumina and Labcorp Expand Precision Oncology Tes...	alpha_vantage	2026-03-20	0.518

Top Negative Events

Title	Source	Date	Score
Recalibrating the epigenetic clock reveals diverge...	pubmed	2026 Mar 2	-0.821
hsa-miR-1246 is Consistently Overexpressed in Sphe...	pubmed	2026-03-28	-0.791
Illumina price gives in to negative pressure - For...	alpha_vantage	2026-03-24	-0.710
Immunological effects of amivantamab in EGFR or ME...	pubmed	2026 Mar 2	-0.660
PD-1 blockade does not enhance alloimmunization af...	pubmed	2026-03-28	-0.660